ライフサイエンスコーパス: mCi

1 Diagnostic doses were 1.0 mCi (37 MBq) in all; therapeutic doses were 150 and 30 m

2 mCi/m(2) (277.5 MBq/m(2); level 3), and 10.0 mCi/m(2) (370 MBq/m(2); level 4).

3 We recommend the dose of 2 x 10.0 mCi/m(2) 1 week apart per cycle for phase 2 studies.

4 an administered activity of 3.89 GBq (105.0 mCi) was obtained, resulting in tumor and lung absorbed

5 Approximately 74 MBq (2.0 mCi) of (99m)Tc(CO)3(NTA) were coinjected with approxima

6 nts divided into 3 dose groups (111 MBq [3.0 mCi], 148 MBq [4.0 mCi], and 185 MBq [5.0 mCi] +/- 10%)

7 e dose-ranging study identified 148 MBq (4.0 mCi) as the optimal dose to obtain diagnostic-quality PE

8 nd accurate images at a dose of 148 MBq (4.0 mCi) for the detection of somatostatin-expressing NETs.

9 dose groups (111 MBq [3.0 mCi], 148 MBq [4.0 mCi], and 185 MBq [5.0 mCi] +/- 10%) to determine the lo

10 : 2.5 mCi/m(2) (92.5 MBq/m(2); level 1), 5.0 mCi/m(2) (185 MBq/m(2); level 2), 7.5 mCi/m(2) (277.5 MB

11 .0 mCi], 148 MBq [4.0 mCi], and 185 MBq [5.0 mCi] +/- 10%) to determine the lowest dose of (64)Cu-DOT

12 radioactivity of 1,222 GBq/micromol (33,024 mCi/micromol; n = 6) at the end of synthesis.

13 ivity of 181.7 +/- 1.1 MBq/mg (4.91 +/- 0.03 mCi/mg).

14 nesthetized and injected with [18F]FEAU (0.1 mCi per mouse); this is followed 2 h after injection by

15 ransit study was performed with 3.7 MBq (0.1 mCi) of (111)In-DTPA in 15 mL of water.

16 udy followed, with ingestion of 3.7 MBq (0.1 mCi) of (111)In-DTPA in 300 mL of water.

17 d TSC in 0.05 mL normal saline: 3.7 MBq (0.1 mCi) on the morning of surgery (1-d protocol) or 18.5 MB

18 l evaluable dogs conditioned with 1.4 to 2.1 mCi/kg Bi-anti-CD45 or 2.0 to 2.7 mCi/kg Bi-anti-TCRalph

19 ity concentrations as low as 114 MBq/mL (3.1 mCi/mL), which is sufficient for analysis of radiochemic

20 icle was labeled with the PET tracer 64Cu (1 mCi/0.1 mg nanoparticles) to yield a PET, magnetic reson

21 nephosphonate (EDTMP) 0.5, 0.5, 0.5, 0.75, 1 mCi/kg.

22 sterile preparation of the operative field 1 mCi of Tc-99 unfiltered was administered by a subareolar

23 h after injection of (18)F-FDG (37 MBq/kg [1 mCi/kg]).

24 per month decreased (10,746 vs. 7,174 mCi [1 mCi = 37 MBq], P < 0.0001), as did the mean (99m)Tc admi

25 28-day cycle in combination with (153)Sm (1 mCi/kg) on day 1.

26 Even with the 1-mCi dose, the radioactive blue dye produced significantl

27 specific activity of 127-370 MBq/mg (3.4-10 mCi/mg) after chromatographic purification.

28 R) chamber coated with radioactive Ni-63 (10 mCi) that fills the CR chamber with a bipolar ionic atmo

29 the range of 300-370 MBq (approximately 8-10 mCi) contribute to image interpretation and justify the

30 the range of 300-370 MBq (approximately 8-10 mCi) do not affect the relative function measurements or

31 tive ions derived from purified air and a 10 mCi (63)Ni foil.

32 , and a single-dose injection of 370 MBq (10 mCi) 131I-TM-601 (0.25-1.0 mg of 131I-TM-601) 2-4 wks af

33 O-water, which was followed by a 370-MBq (10 mCi) dose of 18F-FDG.

34 were intravenously administered 370 MBq (10 mCi) of (123)I-MIP-1072 and (123)I-MIP-1095 2 wk apart i

35 he intravenous administration of 370 MBq (10 mCi) of (18)F-DCFBC.

36 ion of either 111 MBq (3 mCi) or 370 MBq (10 mCi) of florbetapir F 18 in patients with Alzheimer's di

37 tudy involving a labeled dose of 370 MBq (10 mCi) of fluorine 18 fluorodeoxyglucose is estimated to i

38 ts received a dosimetric dose of 370 MBq (10 mCi).

39 n after injection of the tracer (370 MBq [10 mCi]).

40 With an injected dose of 10 mCi (370 MBq) and a 1-hour voiding interval, a patient w

41 A single dose of 10 mCi 131I-TM-601 was well tolerated for 0.25 to 1.0 mg TM

42 ntibody labeled with 185 to 370 Mbq (5 to 10 mCi) [131I]-tracer for dosimetry purposes followed 10 da

43 tolerated; the maximum-tolerated dose was 10 mCi.

44 , or 1.0 mg of TM-601), each labeled with 10 mCi of 131I.

45 between the 111-MBq (3-mCi) and 370-MBq (10-mCi) dose in the visual rating or SUVr.

46 f lesional doses being noted using fixed 100 mCi radioactivities of I-131, no dose-effective relation

47 ctive as high-dose radioiodine (3.7 GBq [100 mCi]) for treating patients with differentiated thyroid

48 tution phase II study, administration of 100 mCi of 131I-m81C6 to recurrent malignant glioma patients

49 In this phase II trial, 100 mCi of 131I-m81C6 was injected directly into the surgica

50 e than patients staged pN1 (median 30 vs 100 mCi, P < 0.0001).

51 valent 48-h activity limits of 3.72 GBq (101 mCi) and 2.45 GBq (66.2 mCi), respectively.

52 dian, 4,033 MBq [109 mCi] vs. 3,811 MBq [103 mCi], P=0.01) but did not differ with respect to sex, hi

53 se was 71.6 mCi (2649.2 MBq; range, 36.6-105 mCi; range, 1354.2-3885 MBq).

54 /- SD], median (131)I dose of 3,996 MBq [108 mCi]).

55 d activity of (131)I (median, 4,033 MBq [109 mCi] vs. 3,811 MBq [103 mCi], P=0.01) but did not differ

56 (maximum, 485 MBq [0.15 mCi/kg; maximum, 12 mCi]) of (18)F-FDG with imaging initiated approximately

57 es ranging from 492 to 1,160 mCi (median, 12 mCi/kg).

58 (> or = 100 mL/min/1.73 m2) was 131I-MIBG 12 mCi/kg, carboplatin 1,500 mg/m2, etoposide 1,200 mg/m2,

59 ematopoietic stem cells (n = 16) received 12 mCi/kg.

60 treatment with [(131)I]MIBG greater than 12 mCi/kg or with a total dose greater than 500 mCi.

61 R cohort, at the initial dose level using 12 mCi/kg of 131I-MIBG and reduced chemotherapy, one in six

62 nt consisted of three cycles of 4.4 GBq (120 mCi) (90)Y-edotreotide each, once every 6 weeks.

63 with (131)I-ch81C6 doses up to 4.44 GBq (120 mCi), including 35 with newly diagnosed tumors (strata A

64 /- 125.8]; mean specific radioactivity, 1200 mCi/mmol +/- 714 [44.4 GBq/mmol +/- 26.4]).

65 (131)I in the range of 2.04-4.81 GBq (55-130 mCi), yields of 59.9% +/- 7.9% (mean +/- SD) at specific

66 We synthesized [(14)C]TETS (14 mCi/mmol, radiochemical purity >99%) by reacting sulfami

67 The MTA was less than 5.18 GBq (140 mCi) in 3%, less than 7.4 GBq (200 mCi) in 8%, and less

68 ed RAI activities of less than 5.18 GBq (140 mCi) rarely exposed blood to more than 200 cGy except in

69 thyroid cancer; median dose, 5,217 MBq [141 mCi]).

70 t-based injected activity (5.3 MBq/kg [0.144 mCi/kg]), fixed acquisition durations (3 min/field of vi

71 received 5.5 MBq/kg (maximum, 485 MBq [0.15 mCi/kg; maximum, 12 mCi]) of (18)F-FDG with imaging init

72 r a standard single injection of 555 MBq (15 mCi) will result in an effective dose equivalent of 5.9

73 (99m)Tc-Glucarate (555 MBq [15 mCi]) was injected 30 min after reperfusion and was foll

74 nitive impairment (MCI; n = 13) (555 MBq [15 mCi], 90-min scan, and arterial blood sampling).

75 R-CHOP, responders received two doses of 15 mCi/m(2) (555 MBq/m(2)) (90)Y-epratuzumab tetraxetan adm

76 (90)Yttrium ((90)Y; 15 mCi/m(2))/(111)In (5 mCi)-DOTA-biotin was injected 24 ho

77 breast tissue associated with a 5.6-GBq (150 mCi) ablation treatment may range from 0.35 to 0.55 Gy,

78 n was most apparent after therapies with 150 mCi.

79 mCi]; range, 12.1 to 42.7 Gbq [328 to 1,154 mCi]) to deliver 25 to 27 Gy to the critical normal orga

80 P. anubis; 166.5 MBq +/- 43.0 (4.50 +/- 1.16 mCi) of 11C-CUMI-101 were injected as an intravenous bol

81 [(131)I]MIBG doses ranging from 492 to 1,160 mCi (median, 12 mCi/kg).

82 c used per month decreased (10,746 vs. 7,174 mCi [1 mCi = 37 MBq], P < 0.0001), as did the mean (99m)

83 rwent preoperative imaging using 666 MBq (18 mCi) of (99m)Tc-folate.

84 ic stem cells (n = 148) were treated with 18 mCi/kg of 131I-MIBG.

85 chemical yield (2.44 +/- 0.70 GBq, 66 +/- 19 mCi, 5 +/- 1%), excellent radiochemical purity (>98%) an

86 I]MIBG administered ranged from 492 to 3,191 mCi.

87 n=29) were injected with NC100692 (1.5+/-0.2 mCi IV) at different times after femoral occlusion (1, 3

88 fter injection of 192 +/- 7 MBq (5.2 +/- 0.2 mCi) [(18)F]SPA-RQ.

89 sulfur colloid-labeled meal and 7.4 MBq (0.2 mCi) of (111)In-DTPA in 120 mL of water.

90 uid study (300 mL of water with 7.4 MBq [0.2 mCi] of (111)In-diethylenetriaminepentaacetic acid) was

91 ( approximately 7.4 MBq [ approximately 0.2 mCi]) into 3 healthy volunteers and then performing dual

92 The activities ranged from 81.4 MBq (2.2 mCi) to 1,406 MBq (38 mCi) over the volume range of 3-9

93 ical purity (>99%), specific activity of 2.2 mCi/mg of NP, and high stability (i.e., no detectable di

94 its of 3.72 GBq (101 mCi) and 2.45 GBq (66.2 mCi), respectively.

95 uct ( approximately 74 MBq [ approximately 2 mCi]) and (131)I-OIH ( approximately 7.4 MBq [ approxima

96 mer ( approximately 74 MBq [ approximately 2 mCi]) and 7.4-11.1 MBq (200-300 micro Ci) of (131)I-OIH

97 Approximately 74 MBq (2 mCi) of (99m)Tc(CO)(3)(NTA) were coinjected with 9.25 MB

98 infarcted myocardium, we injected 74 MBq (2 mCi) of (99m)Tc-sestamibi (Cardiolite) intravenously 48

99 Study participants received 74 MBq (2 mCi) of intravenous (89)Zr-DFO-daratumumab.

100 With a dose of 2 mCi/kg Bi, further trials using radioimmunotherapy with

101 Fifteen patients received a tracer (1 to 2 mCi) and therapeutic injection (10 to 20 mCi) of intra-O

102 patients (n = 27) received 185-740 MBq (5-20 mCi/m(2)) of (90)Y-J591.

103 ation were (18)F-FDG dose (259-740 MBq [7-20 mCi]) uptake time (45-90 min), sedation (never to freque

104 Dose limiting toxicity (DLT) was seen at 20 mCi/m(2), with two patients experiencing thrombocytopeni

105 ximum, 740 MBq [20 mCi/1.7 m(2); maximum, 20 mCi]) of (11)C-methionine intravenously.

106 egan 5-15 min after injection of 740 MBq (20 mCi) per 1.7 m(2) of body surface area.

107 eived 740 MBq/1.7 m(2) (maximum, 740 MBq [20 mCi/1.7 m(2); maximum, 20 mCi]) of (11)C-methionine intr

108 tomography procedure: after injection of 20 mCi of [(11)C]flumazenil, dynamic emission images of the

109 o 2 mCi) and therapeutic injection (10 to 20 mCi) of intra-Ommaya 131I-3F8.

110 graphy and gamma imaging after a 740-mBq (20-mCi) technetium 99m sestamibi injection.

111 Dose-limiting toxicity was reached at the 20-mCi dose, when transient elevations in intracranial pres

112 GBq (140 mCi) in 3%, less than 7.4 GBq (200 mCi) in 8%, and less than 9.25 GBq (250 mCi) in 19%.

113 mpiric administered activity of 7.4 GBq (200 mCi) would exceed the MTA in 8%-15% of patients less tha

114 can be obtained in quantities >7.4 GBq (200 mCi), ready for injection (20 +/- 5%, non-decay correcte

115 ) of (18)F-fluoride, more than 7.4 GBq (>200 mCi) of (18)F-AMBF3-TATE were obtained in 25 min (n = 5)

116 tely 50-60% and specific activities of >2000 mCi/micromol.

117 fter intravenous injection of 7.77 MBq (0.21 mCi) of (18)F-FDG per kilogram, a standard whole-body CT

118 fter intravenous injection of 7.77 MBq (0.21 mCi) of 18F-FDG per kilogram of body weight, PET emissio

119 was escalated from 444 to 777 MBq/kg (12-21 mCi/kg) using a 3 + 3 design.

120 , where the second infusion was capped at 21 mCi/kg.

121 ic administration of 1,739-8,066 MBq (47-218 mCi) of (131)I.

122 a specific activity that is greater than 220 mCi/mmol.

123 se of Tc-99 administered was 1.157 +/- 0.230 mCi.

124 Two dogs receiving 2.26 and 3.25 mCi/kg of (213)Bi rejected their grafts at day +127 and

125 aging 3 h after FDG administration (13 to 25 mCi), after which carotid plaque FDG uptake was determin

126 ities ranging from 5.55 to 9.25 GBq (150-250 mCi).

127 nistered activities of 7.4-9.25 GBq (200-250 mCi) frequently exceeded the calculated MTA in patients

128 Two source platters containing ~ 250 mCi each of (137)Cs brachytherapy seeds are mounted abov

129 (200 mCi) in 8%, and less than 9.25 GBq (250 mCi) in 19%.

130 a lowering of MTA to less than 9.25 GBq (250 mCi) were age at dosimetry greater than 45 y, the female

131 However, administration of 9.25 GBq (250 mCi) would exceed the MTA in 22% of patients less than 7

132 ated using targets containing ~0.96 GBq (~26 mCi) of (211)At.

133 ty-six patients were treated with 102 to 298 mCi (3774-11 026 MBq) 131I, delivering an estimated 5.3

134 , 2 patients received 5.55-11.1 GBq (150-299 mCi) of (131)I.

135 s than 150,000/microL received a dose of 0.3 mCi/kg.

136 fic activities of 37-111 MBq microg(-1) (1-3 mCi microg(-1)).

137 (control) was done by injecting 48 MBq (1.3 mCi) of (99m)Tc-MAG3, and renography was performed.

138 ups, all dogs conditioned with less than 1.3 mCi/kg Bi rejected their grafts.

139 min with specific activities as high as 2.3 mCi/nmol (97.5% radiochemical yield) is presented.

140 whereas dogs receiving (213)Bi doses of 3.3 mCi/kg or greater achieved high level donor chimerism.

141 3 radiotracer injection is 2,487.6 MBq (67.3 mCi).

142 were administered (intravenously) 111 MBq (3 mCi) of (125)I-DCIBzL, 111 MBq (3 mCi) of (125)I-NaI, an

143 111 MBq (3 mCi) of (125)I-DCIBzL, 111 MBq (3 mCi) of (125)I-NaI, an equivalent amount of nonradiolabe

144 Patients received approximately 111 MBq (3 mCi) of (89)Zr-IAB22M2C (at minibody mass doses of 0.2,

145 ravenous administration of either 111 MBq (3 mCi) or 370 MBq (10 mCi) of florbetapir F 18 in patients

146 eaningful differences between the 111-MBq (3-mCi) and 370-MBq (10-mCi) dose in the visual rating or S

147 abel-recommended dose of 740-1100 MBq (20-30 mCi) of technetium 99m-sestamibi is estimated to involve

148 After injection with 25-30 mCi (925-1110 MBq) of technetium 99m sestamibi, patients

149 q) in all; therapeutic doses were 150 and 30 mCi (5,550 and 1,110 MBq), each to half of the patients.

150 wn whether low-dose radioiodine (1.1 GBq [30 mCi]) is as effective as high-dose radioiodine (3.7 GBq

151 rst fraction in each cycle was 1,110 MBq (30 mCi) of (131)I conjugated to 5 mg of antibody.

152 ved an administered activity of 1110 MBq (30 mCi), and 2 developed toxicity that required stem cell i

153 ing administered activities of 1,110 MBq (30 mCi); administered activities of 2,775 MBq (75 mCi) or m

154 erwent BSGI with intravenous injection of 30 mCi (1110 MBq) of technetium 99 ((99m)Tc)-sestamibi and

155 A total of 30 mCi 99mTc-sestamibi was injected at one minute into the

156 Multiple doses of 30 mCi/m(2) are well tolerated.

157 uppression; however, up to three doses of 30 mCi/m(2) could be safely administered.

158 specific activity was 85 GBq/micromol (2,300 mCi/micromol) (end of synthesis).

159 and toxicity of treatment with 11.1 GBq (300 mCi) of (131)I-MIBG per cycle.

160 Treatment comprised 11.1 GBq (300 mCi) per course and minimum intervals of 3 mo.

161 (131)I-MIBG at a fixed dose of 11.1 GBq (300 mCi) per cycle is safe and offers effective palliation o

162 ent disease received 0.4 mCi/kg (maximum, 32 mCi/kg) (9)(0)Y-ibritumomab tiuxetan, fludarabine, and 2

163 %) with high specific radioactivities (>3300 mCi/mumol).

164 itumomab ranged from 629 to 1,258 MBq (17-34 mCi).

165 specific activity of 12.9 GBq/micromol (349 mCi/micromol, n=7) at the end of synthesis.

166 ishing the recommended cumulative dose as 36 mCi/kg.

167 ged from 81.4 MBq (2.2 mCi) to 1,406 MBq (38 mCi) over the volume range of 3-9 mL.

168 ls) were labeled with 11.1-14.8 MBq (0.3-0.4 mCi) of (111)In-oxyquinoline and then injected into the

169 atients with persistent disease received 0.4 mCi/kg (maximum, 32 mCi/kg) (9)(0)Y-ibritumomab tiuxetan

170 At the maximum tolerated dose (0.4 mCi/kg [14.8 MBq/kg]), TTP and DR in complete responders

171 > or = 150,000/microL received a dose of 0.4 mCi/kg of (90)Y-ibritumomab tiuxetan, whereas those with

172 ial in which (90)Y-ibritumomab tiuxetan (0.4 mCi/kg) was added to the fludarabine, cyclophosphamide c

173 Zevalin (0.4 mCi/kg) was given to responders not in CR before transpl

174 at least twice the conventional dose of 0.4 mCi/kg, a weight-based strategy at 0.8 mCi/kg would have

175 e 90Y ibritumomab tiuxetan (14.8 MBq/kg [0.4 mCi/kg]) followed by high-dose BEAM.

176 An administered activity of 1.72 GBq (46.4 mCi) delivered the putative MTD of 27.25 Gy to the lungs

177 .3 mSv for an administration of 200 MBq (5.4 mCi) of (68)Ga-FAPI-46 (1.56 +/- 0.26 mSv from the PET t

178 .3 mSv for an administration of 200 MBq (5.4 mCi) of (68)Ga-FAPI-46 (1.56+/- 0.26 mSv from the PET tr

179 Then, 3.5 +/- 0.2 GBq (94.7 +/- 5.4 mCi) of (90)Y-DOTATOC were administered into the proper

180 with averaged 803 +/- 200 MBq (21.7 +/- 5.4 mCi) of (99m)Tc injected at stress.

181 A total of 4 mCi (148 MBq) of FDG was administered before the procedu

182 for the 14-min acquisition or 125.8-MBq (3.4-mCi) injected dose for the 10-min acquisition.

183 ved an administered activity of 1480 MBq (40 mCi), and 2 developed hematologic toxicity that required

184 cific activity of 1,051 GBq/micromol (28,400 mCi/micromol; n=5) at the end of synthesis.

185 rived organ mass compared with 16.0 GBq (433 mCi) that would otherwise have been given had therapy be

186 an administered activity of 17 MBq/kg (0.45 mCi/kg), the effective dose equivalent was about 5 mSv o

187 ges of (18)F-PEG(6)-IPQA up to 128 MBq (3.47 mCi) per injection should be safe for administration in

188 n administration of less than 1,780 MBq (<48 mCi) of (11)C-NPA yields an organ dose of under 50 mSv (

189 udy, after diagnostic doses of 2, 1, and 0.5 mCi (74, 37, and 18.5 MBq), mean 2-d Rx/Dx values in 24,

190 g of surgery (1-d protocol) or 18.5 MBq (0.5 mCi) on the afternoon before surgery (2-d protocol).

191 s were treated with mAb 6D2 labeled with 1.5 mCi (1 Ci = 37 GBq) of the beta-emitter 188-Rhenium (188

192 e fasted for 6 h before 5.55 x 10(7) Bq (1.5 mCi) of (18)F-FDG were injected 1 h before the imaging p

193 Only one dog conditioned with 1.5 mCi/kg Bi-anti-TCRalphabeta had stable engraftment, wher

194 The recommended dose for (90)Y-J591 is 17.5 mCi/m(2).

195 Tumor-bearing mice were treated with 2.5 mCi (18)F-FDG, which is equivalent to the physiological

196 One hour after administration of 2.0-2.5 mCi (74.0-93.5 MBq) of fluorodeoxyglucose, 5-minute PET

197 successively at one of four dose levels: 2.5 mCi/m(2) (92.5 MBq/m(2); level 1), 5.0 mCi/m(2) (185 MBq

198 re injected with 2.22 +/- 0.19 GBq (60 +/- 5 mCi) of (82)Rb and imaged dynamically for 6 min at rest

199 ), 5.0 mCi/m(2) (185 MBq/m(2); level 2), 7.5 mCi/m(2) (277.5 MBq/m(2); level 3), and 10.0 mCi/m(2) (3

200 hours after tracer injection (mean dose, 9.5 mCi +/- 3.4 [standard deviation] [351.5 MBq +/- 125.8];

201 lone, GLV-1h153 and (131)I ( approximately 5 mCi), (131)I alone, or PBS, and followed for tumor growt

202 (90)Yttrium ((90)Y; 15 mCi/m(2))/(111)In (5 mCi)-DOTA-biotin was injected 24 hours later.

203 the intravenous administration of 185 MBq (5 mCi) (123)I-ADAM.

204 ter intravenous administration of 185 MBq (5 mCi) (99m)Tc-pertechnetate.

205 ter intravenous administration of 185 MBq (5 mCi) of (123)I-ADAM.

206 the intravenous administration of 185 MBq (5 mCi) of (123)I-IMPY.

207 mg of cG250 antibody labeled with 185 MBq (5 mCi) of (131)I.

208 Patients received 185 MBq (5 mCi) of (89)Zr-IAB2M and Df-IAB2M at total mass doses of

209 erwent injection of approximately 185 MBq (5 mCi) of (99m)Tc-tetrofosmin at peak stress, followed by

210 -J591) (2 mg of J591 labeled with 185 MBq [5 mCi] of (111)In via the chelating agent DOTA).

211 iodine-131 tositumomab (dosimetric dose of 5 mCi on day -19 and therapeutic dose of 0.75 Gy on day -1

212 Patients received 5 mCi BMIPP within 30 h of symptom cessation.

213 atients underwent dosimetry (day -21) with 5 mCi (185 MBq) 111In-ibritumomab tiuxetan following 250 m

214 nt level would correspond to a 92.5-MBq (2.5-mCi) injected dose for the 14-min acquisition or 125.8-M

215 for an average patient dose of 1,850 MBq (50 mCi) in 10 mL.

216 achieve the target RMI ranged from 22 to 50 mCi/kg, with cumulative RMI of 3.2 to 8.92 Gy.

217 mCi/kg or with a total dose greater than 500 mCi.

218 1)I administered activities of 19.2 GBq (520 mCi) after adjustment for CT-derived organ mass compared

219 of [131I]tositumomab (median, 19.4 Gbq [525 mCi]; range, 12.1 to 42.7 Gbq [328 to 1,154 mCi]) to del

220 of high specific activity (2.1 GBq/mmol, 58 mCi/mmol) (1 Ci = 37 GBq) and no detectable dilution of

221 Activity of 7.4-22.2 MBq (0.2-0.6 mCi) localized within the synthetic lesion.

222 he injection of 669 +/- 97 MBq (18.1 +/- 2.6 mCi) of 11C-DASB.

223 PA group after administration of 96 MBq (2.6 mCi) of the tracer.

224 ects were injected with 170-244 MBq (4.6-6.6 mCi) of BMS747158 intravenously.

225 edian 90Y-ibritumomab tiuxetan dose was 71.6 mCi (2649.2 MBq; range, 36.6-105 mCi; range, 1354.2-3885

226 rmed with a bolus injection of 2,220 MBq (60 mCi) of 15O-water, which was followed by a 370-MBq (10 m

227 Repeat dosing at 45 to 60 mCi/m(2) was associated with dose-limiting myelosuppress

228 for THW vs. 4,958 +/- 2,294 MBq [134 +/- 62 mCi] for rhTSH), THW was associated with a lower rate of

229 le-body retention was scaled to 2.44 GBq (66 mCi) to give the same dose rate of 43.6 rad/h in the lun

230 activities of 200 +/- 26 MBq/mg (5.4 +/- 0.7 mCi/mg) were obtained, with > or =95% of the radioactivi

231 1.4 to 2.1 mCi/kg Bi-anti-CD45 or 2.0 to 2.7 mCi/kg Bi-anti-TCRalphabeta.

232 was dose limiting at 75 mCi/m(2), and the 70-mCi/m(2) dose level was determined to be the single-dose

233 (n = 28) received 370-2,775 MBq/m(2) (10-75 mCi/m(2)) of (177)Lu-J591 and 5 groups of patients (n =

234 Myelosuppression was dose limiting at 75 mCi/m(2), and the 70-mCi/m(2) dose level was determined

235 i); administered activities of 2,775 MBq (75 mCi) or more were associated with symptoms in 40% of pat

236 eescalation study in 15 dogs with 2.7 to 0.8 mCi/kg Bi.

237 f 0.4 mCi/kg, a weight-based strategy at 0.8 mCi/kg would have resulted in a wide range of RAD; nearl

238 nistered activity per patient (36.5 vs. 23.8 mCi, P < 0.0001).

239 on Drug Research Committee is 1.58 GBq (42.8 mCi).

240 ftment was achieved with doses of 3.6 to 8.8 mCi/kg Bi, but signs of liver toxicity were noted in all

241 completion of the ablation, an additional 8 mCi (296 MBq) of FDG was administered to assess ablation

242 A drawn dose of 8 mCi (296 MBq) of technetium 99m sestamibi was administer

243 An 8-mCi (+/-10%) dose of (18)F FSPG was given to five subjec

244 ole-body retention threshold of 2.96 GBq (80 mCi) at 48 h has been used to limit the radioactivity of

245 The MTD of (131)I-ch81C6 is 2.96 GBq (80 mCi) because of dose-limiting hematologic toxicity.

246 toxicity defined the MTD to be 2.96 GBq (80 mCi) for all patients, regardless of treatment strata.

247 ns the administered activity to 2.96 GBq (80 mCi) whole-body retention at 48 h after administration t

248 is pediatric patient, where the 2.96-GBq (80 mCi) whole-body retention was scaled to 2.44 GBq (66 mCi

249 inical (82)Rb injection of 2 x 1,480 MBq (80 mCi) would result in a mean effective dose of 3.7 mSv us

250 f the adult female reference phantom when 80 mCi of (131)I are in the body and 90% of this is uniform

251 In this work, the 80-mCi activity retention limit is used to derive lung-abso

252 The implications of the 80-mCi rule are also examined.

253 A dose-rate-based version of the 80-mCi rule is derived and used to demonstrate application

254 With this definition, the 80-mCi rule was generalized by calculating the activity req

255 ed activity (5,661 +/- 2,997 MBq [153 +/- 81 mCi] for THW vs. 4,958 +/- 2,294 MBq [134 +/- 62 mCi] fo

256 herapy ranged from 38 to 67 GBq (1,030-1,810 mCi).

257 labeled anti-CD45 mAb (dose (213)Bi=2.26-4.9 mCi/kg) in six to eight injections.

258 hy (PET) and CT (hereafter, PET/CT) with 6.9 mCi of fluorodeoxyglucose (FDG) and magnetic resonance (

259 was 15.1 +/- 10.8 mGy/MBq (55.8 +/- 39.8 cGy/mCi) 90Y-hMN-4 IgG (n = 29 tumors in 8 patients), with a

260 Average dosimetry ratio (Gy/mCi) of the therapy/tracer administration was 0.88 (+/-

261 as, 2.4 muGy/MBq (19, 19, 10.4, and 8.9 mrad/mCi, respectively).

262 ffective dose was 5.7 microSv/MBq (21.1 mrem/mCi).

263 and 32.3 microSv/MBq (109, 108, and 120 mrem/mCi), respectively.

264 dose was approximately 17 muSv/MBq (62 mrem/mCi), with the gallbladder receiving the highest dose of

265 fective dose was 6.98 microGy/MBq (25.8 mrem/mCi).

266 0020 mGy/MBq (0.0086, 0.0006, and 0.0074 rad/mCi) for the ovaries, testes, and red marrow, respective

267 295 rad/mCi) and 0.00709 mGy/MBq (0.0262 rad/mCi), respectively.

268 and spleen were 0.00797 mGy/MBq (0.0295 rad/mCi) and 0.00709 mGy/MBq (0.0262 rad/mCi), respectively.

269 s, with a dose of 0.0393 mGy/MBq (0.1455 rad/mCi).

270 0.0002 to 0.0393 mGy/MBq (0.0006-0.1455 rad/mCi).

271 ecreases with a value of 7.5 mGy/MBq (28 rad/mCi) for a newborn.

272 adder wall dose to 0.0885 mGy/MBq (0.327 rad/mCi) or 0.128 mGy/MBq (0.473 rad/mCi), respectively, and

273 eceived an average of 0.12 mGy/MBq (0.43 rad/mCi) (range, 0.098-0.15 mGy/MBq).

274 (0.327 rad/mCi) or 0.128 mGy/MBq (0.473 rad/mCi), respectively, and the effective dose to 0.0149 mSv

275 large intestines (161.26 muGy/MBq [0.597 rad/mCi] and 184.59 muGy/MBq [0.683 rad/mCi]).

276 .597 rad/mCi] and 184.59 muGy/MBq [0.683 rad/mCi]).

277 less than the value of 0.45 mGy/MBq (1.7 rad/mCi) previously accepted.

278 d gallbladder wall, 0.193 mGy/MBq (0.716 rad/mCi).

279 ated in this study of 0.21 mGy/MBq (0.77 rad/mCi) is approximately a factor of 2 less than the value

280 the highest dose (229.50 muGy/MBq [0.849 rad/mCi]), followed by the small and large intestines (161.2

281 inary bladder wall, 0.258 mGy/MBq (0.955 rad/mCi), and gallbladder wall, 0.193 mGy/MBq (0.716 rad/mCi

282 The blood absorbed dose (cGy/37 MBq [rad/mCi] administered) was reduced from 2.54 +/- 0.91 (mean

283 t-specific mean 90Y dose (cGy/37 MBq, or rad/mCi) was 0.53 (0.32-0.78) to whole body, 3.75 (0.63-6.89

284 se equivalent was 0.0106 mSv/MBq (0.0392 rem/mCi).

285 effective dose to 0.0149 mSv/MBq (0.0551 rem/mCi) or 0.0171 mSv/MBq (0.0634 rem/mCi), respectively.

286 .0551 rem/mCi) or 0.0171 mSv/MBq (0.0634 rem/mCi), respectively.

287 effective dose was 0.019 mSv/MBq (0.072 rem/mCi).

288 effective dose was 0.025 mSv/MBq (0.0922 rem/mCi).

289 effective dose was 28.79 muGy/MBq (0.107 rem/mCi).

290 fective dose of (18)F-FPPRGD2 was 0.1462 rem/mCi +/- 0.0669 (0.0396 mSv/MBq +/- 0.0181).

291 by the heart wall at 0.048 mSv/MBq (0.18 rem/mCi).

292 of 2.01 x 10(-2) mSv/MBq (7.43 x 10(-2) rem/mCi).

293 e was the kidneys at 0.066 mSv/MBq (0.24 rem/mCi), followed by the heart wall at 0.048 mSv/MBq (0.18

294 g model) and uptake in the spleen (0.250 rem/mCi +/- 0.168 [0.068 mSv/MBq +/- 0.046]) and large intes

295 ary clearance through the kidneys (0.360 rem/mCi +/- 0.185 [0.098 mSv/MBq +/- 0.050]) and bladder (0.

296 h an effective dose of 0.41 mSv/MBq (1.5 rem/mCi).

297 q +/- 0.046]) and large intestine (0.529 rem/mCi +/- 0.236 [0.143 mSv/MBq +/- 0.064]).

298 work is approximately 0.16 mSv/MBq (0.60 rem/mCi).

299 8 mSv/MBq +/- 0.050]) and bladder (0.862 rem/mCi +/- 0.436 [0.233 mSv/MBq +/- 0.118], voiding model)

300 tients, but no correlation of Rx/Dx with the mCi in the diagnostic dose was seen.